Revolutionizing Cancer Care with Immunotherapy
In the early 2000s, the potential of immunotherapy—harnessing the body’s immune system to combat diseases—was met with skepticism and limited understanding. At the time, only a handful of immunotherapy drugs had FDA approval.
Fast forward to today, and immunotherapy has transformed oncology. Groundbreaking advancements like therapeutic cancer vaccines, immune checkpoint inhibitors, CAR-T cell therapies, cytokines, and oncolytic viruses have redefined how we fight cancer.1 Since 2010, over 30 immunotherapy drugs have been approved to treat 25 types of cancer.2
The impact is undeniable. Immunotherapies are now widely used across numerous cancer types, delivering better outcomes and extending lives. With more than 1,000 immunotherapy treatments currently in clinical trials, the future holds even greater promise to revolutionize cancer care and bring hope to countless patients worldwide.3
1 PhRMA. 40 years of cancer immunotherapy research: Paving the way for breakthrough treatments. November 2022.
2 Cancer Research Institute. Regulatory Approval Timeline of Active Immunotherapies.
3 ClinicalTrials.gov. https://clinicaltrials.gov/search?cond=cancer&intr=Immunotherapy.
Our Work in Action
With the support of a unique ecosystem and policy environment that foster transformative advancements, this progress positions America as the global leader in biopharmaceutical innovation.
